SCHEDULE OF CHANGES IN INVESTMENT (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Oct. 31, 2025 |
Oct. 31, 2024 |
Jul. 31, 2025 |
|
| Restructuring Cost and Reserve [Line Items] | |||
| Funding (including the value of the BC Therapeutics Options) | $ 75,000 | $ 75,000 | |
| Share of losses: | (44,830) | (71,515) | |
| BC Therapeutics Inc [Member] | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Beginning balance | 524,278 | $ 418,490 | $ 418,490 |
| Funding (including the value of the BC Therapeutics Options) | 75,000 | 330,000 | |
| Share of losses: | (44,830) | (224,212) | |
| Ending balance | $ 554,448 | $ 524,278 | |
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of investment in equity method investee and investment in and advance to affiliate. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|